[ @entity7135 in a boarding school: a XXXX -resistant secondary case while under chemoprophylaxis].

@entity1 @entity295 @entity114 @entity43523 @entity693 @entity281 @entity1800 @entity1215 @entity7135 @entity3631
An epidemic of @entity7135 after an influenza outbreak in a community of 49 @entity1 (14-18 years) and 8 adults in a boarding-school is reported. The first @entity1 died with all symptoms of the @entity43523 . Several hours later, two other @entity1 developed severe @entity295 with @entity693 and @entity693 respectively. @entity3631 group B susceptible to @entity114 and @entity1215 was isolated. Within the next 8 hours, chemoprophylaxis with @entity1215 (600 mg twice daily) was started and maintained for 4 days for the whole community. Throat cultures had not been obtained before prophylaxis. Ten other symptomatic @entity1 were admitted to the hospital and treated by @entity114 infusion. The results of blood and cerebrospinal fluid cultures were negative, and treatment was therefore discontinued. Five days after the death of the first @entity1 , another @entity1 died with full-blown @entity43523 while on chemoprophylaxis. The neisseriae isolated from this @entity1 were @entity1215 -resistant. Serological investigations in all @entity1 admitted to hospital revealed the existence of concomitant @entity281 with influenza A and B in this school. We assume that the @entity1800 made way for the outbreak of the @entity7135 and for the high rate of @entity7135 . Chemoprophylaxis with @entity1215 should not be continued for longer than 2 to 3 days, otherwise the risk of occurrence of @entity1215 resistant strains of @entity3631 increases. Hitherto such strains have rarely been isolated in clinically manifest disease.
